Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Multiple myeloma / Plasma cell neoplasm
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 467 for your search:
Start Over
An Expanded Access Program For Lenalidomide Plus Dexamethasone In Previously Treated Subjects With Multiple Myeloma
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-MM-016, FHCRC-2068.00, CELGENE-CC-5013-MM-016, NCT00179647
Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SHCZH-2010-CT-001, NCT01249690
Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation
Phase: Phase IV
Type: Health services research, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Plerixafor-UF01, NCT01339572
Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AAAJ2355, NCT01731886
A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma
Phase: Phase IV
Type: Treatment
Status: Active
Age: Under 66
Sponsor: Other
Protocol IDs: PAD VS VCD Clinical Protocol, NCT01868828
A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR104583, 26866138MMY4073, NCT02268890
Autologous Bone Marrow Transplantation (BMT) Compared With Allogeneic BMT in Multiple Myeloma
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 55
Sponsor: Other
Protocol IDs: HORCSCT-0901, NCT00998270
Autologous Transplant for Multiple Myeloma
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 2004LS001, MT2003-13, 0312M54569, UMN-2004LS001, UMN-MT2003-13, UMN-0312M54569, NCT00293306, NCT00177047
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02057, ECOG-E3A06, CDR0000682012, E3A06, U10CA180820, U10CA021115, NCT01169337
Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: Busulfan-2013, NCT01800643
Treatment Optimization in Patients With Untreated Multiple Myeloma
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GERMAIN, 2012-003023-38, NCT02145598
"Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 181114, NCT02419118
Stem Cell Transplant for Hematological Malignancy
Phase: Phase III
Type: Treatment
Status: Active
Age: 54 and under
Sponsor: Other
Protocol IDs: 0107M05202, MT2001-02, NCT00176930
Multi Centre Trial of DSMM for Newly Diagnosed Multiple Myeloma up to 60 Years
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: DSMM V, NCT00546988
Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose Chemotherapy
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EmNa (2001-004956-38), EudraCT-No: 2004-004956-38, NCT00571168
UARK 2008-01, Total Therapy 4 - A Phase III Trial for Low Risk Myeloma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: UARK 2008-01, NCT00734877
Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: LenaMain-Trial, NCT00891384
Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line Treatment for Myeloma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: MHOPES-myeloma09, NCT00892346
Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma
Phase: Phase III
Type: Treatment
Status: Active
Age: 60 to 75
Sponsor: Other
Protocol IDs: DSMM XIII, NCT01090089
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: APL-C-001-09, NCT01102426
Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 1005011049, X05324, NCT01146834
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Pharmaceutical / Industry
Protocol IDs: 10-106, NCT01208662
Studies in Patients With Multiple Myeloma and Renal Failure Due to Myeloma Cast Nephropathy
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: P081226, NCT01208818
Start Over